Chiropractors in Sanborn, NY Accepting Medicare
4 Chiropractors found. Showing 1 - 4
 Dr. Heather Lea Mahley, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 5901 Baer Rd, Sanborn, NY 14132 Phone: 716-731-4696 |
 Dr. Stephen Michael Dubuc, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2293 Saunders Settlement Rd, Sanborn, NY 14132 Phone: 716-297-9123 Fax: 716-297-6717 |
 Kummer Chiropractic Pc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 5215 Townline Rd, Sanborn, NY 14132 Phone: 716-731-2225 |
Dr. Daniel J. Kummer, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 5215 Townline Rd, Sanborn, NY 14132 Phone: 716-731-2225 |
News Archive
New 'nanoPCR' technology can accurately diagnose COVID-19 in less than 20 minutes
A "nanoPCR" technology was developed for the point-of-care (POC) diagnosis of coronavirus disease-19 (COVID-19).
Possible new target for anticancer therapeutics
New data, generated in mice, by Pierre Sonveaux and colleagues, at University catholique de Louvain, Belgium, have identified a potential new target for anticancer therapeutics.
Social isolation could be linked to increased inflammation in the body
Social isolation could be associated with increased inflammation in the body new research from the University of Surrey and Brunel University London has found.
JPO issues patent grant for Apricus's Femprox
Apricus Biosciences, Inc., backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Japanese Patent Office has issued a Decision to Grant a Patent for the Company's application on Femprox entitled, Compositions and Methods for Amelioration of Human Female Sexual Dysfunction.
Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD
Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.
› Verified 3 days ago